Use this URL to cite or link to this record in EThOS:
Title: Targeting regulatory T cells for therapeutic gain in cancer therapy
Author: Solomon, Isabelle
ISNI:       0000 0004 9352 8321
Awarding Body: UCL (University College London)
Current Institution: University College London (University of London)
Date of Award: 2020
Availability of Full Text:
Access from EThOS:
Full text unavailable from EThOS. Please try the link below.
Access from Institution:
Regulatory T cell (Treg) abundance associates with diminished anti-tumour immunity and poor prognosis in human epithelial cancers, underscoring their value as an immunotherapy target. There has been limited clinical success in targeting this cell population likely due to a lack of consensus on the most selective targets for depletion of Treg cells, and the limited mechanistic insight into the activity of these antibodies in vivo. Recent work from our lab (Vargas et al., 2017) demonstrates that CD25 (the high affinity alpha receptor subunit for IL-2) is a selective target for the depletion of regulatory T cells in mouse and human malignancies. However, despite being a selective target, aCD25PC61 lacks single agent activity against tumours. Based on this, two projects were developed, both focusing on CD25 as a target for Treg depletion. The first project focused on the development of a bispecific antibody targeting both CD25 and PD-L1, with the rationale being that Treg depletion would be targeted to the tumour (due to PD-L1 upregulation in the tumour microenvironment). The bispecific antibody was developed in the lab, and its production, characterisation and activity in vitro and in vivo is discussed in depth in Chapter 4. The second project was initiated as a hypothesis that the in vivo activity of available anti-CD25 mAbs targeting human and mouse Treg cells, is likely limited by their IL-2 blocking activity. By developing a CD25 antibody which does not block IL-2 signalling, this hypothesis was tested in vivo in various mouse tumour models. The work presented in this thesis demonstrates the critical importance of endogenous IL-2 to the function of the CD4 and CD8 effector compartments in the context of Treg depletion and that this is key for the superior anti-tumour activity of aCD25NIB.
Supervisor: Not available Sponsor: Not available
Qualification Name: Thesis (Ph.D.) Qualification Level: Doctoral
EThOS ID:  DOI: Not available